13F Holdings
中文EN

AMRN AMARIN CORP PLC\UK

Pharmaceutical Preparations · Nasdaq · SEC CIK 897448 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-22.3%
TTM net income YoY77.8%
TTM EPS YoY81.0%
Revenue 3-yr CAGR-18.3%
Net income 3-yr CAGR—

Margins

Gross margin40.9%
Operating margin-18.2%
Net margin-10.9%
FCF margin—
EBITDA margin—

Returns

ROE-4.2%
ROA-3.0%
ROIC (approx.)-8.1%
Asset turnover0.27x

Leverage & solvency

Liabilities / assets29.9%
Debt / equity0.00x
Current ratio3.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$213.65M$228.61M$306.91M$369.19M$583.19M
Cost of revenue————$121.33M
Gross profit$120.87M$81.38M$165.54M$242.48M$461.86M
R&D expense$19.81M$20.87M$22.22M$30.41M$29.31M
SG&A expense$115.00M$152.31M$199.94M$304.42M$408.33M
Operating income-$50.17M-$91.80M-$67.59M-$105.87M$10.50M
Interest expense$7,000$7,000$8,000$15,000$129,000
Pretax income-$36.05M-$77.20M-$53.67M-$103.81M$11.29M
Income tax$2.75M$4.98M$5.44M$2.00M$3.56M
Net income-$38.80M-$82.18M-$59.11M-$105.80M$7.73M
EBITDA—-$91.70M-$67.39M-$105.27M$11.10M
EPS (basic)-0.09-0.20-0.15-0.260.02
EPS (diluted)-0.09-0.20-0.15-0.260.02
Weighted avg. shares (diluted)414.98M410.94M407.65M401.15M402.48M
Balance sheet
Cash & equivalents$134.66M$121.04M$199.25M$217.67M$219.45M
Short-term investments$167.93M$173.18M$121.41M$91.69M$234.67M
Receivables$126.83M$122.28M$133.56M$130.99M$163.65M
Inventory$195.91M$166.05M$258.62M$228.73M$234.68M
Current assets$649.88M$595.40M$724.98M$689.10M$878.73M
PP&E, net$12,000$16,000$114,000$874,000$1.43M
Intangibles$13.37M$16.39M$19.30M$21.78M$23.55M
Total assets$670.77M$685.35M$831.68M$886.18M$1.07B
Current liabilities$194.46M$179.95M$259.28M$259.48M$370.68M
Short-term debt————$0
Total liabilities$211.49M$199.17M$279.59M$290.85M$400.97M
Shareholders' equity$459.28M$486.18M$552.10M$595.33M$667.10M
Shares outstanding416.21M411.58M408.82M408.82M396.60M
Cash flow statement
Operating cash flow$6.73M-$31.02M$6.88M-$180.09M-$66.54M
Investing cash flow$8.83M-$45.98M-$25.52M$175.29M$104.10M
Financing cash flow-$2.03M-$1.44M$230,000-$379,000-$5.07M
Depreciation & amortization—$100,000$200,000$600,000$600,000
Stock-based compensation$13.94M$17.70M$15.65M$26.21M$36.94M

Free plan shows the latest 5 periods; Pro shows all 20 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.